Cambridge Antibody Technology announces changes to the board and executive group

14-Jan-2005

Cambridge Antibody Technology announces changes to the Company's Board of Directors and Executive Group. Dr David Glover, Chief Medical Officer at CAT, will take early retirement from the Company and the Board after the Company's Annual General Meeting (AGM) on 4 February 2005. David was appointed to the Board of CAT in July 1997, having joined the Company as Vice President Medical Development in November 1994. As the first senior management appointee from the pharmaceutical industry to the Company, David played a fundamental role in establishing product development capabilities and expertise in CAT. He has made a major contribution to the Company's successful institutional fundraising activities. Following David's retirement, Dr Patrick Round, VP Development at CAT, will assume responsibility for all of CAT's development activities and will join the Company's Executive Group, which has responsibility for the operational management of the Company. Before joining CAT in May 2004, Patrick was Director of Development at Celltech and has also held positions at Glaxo Wellcome, Novo Nordisk A/S, Denmark and Novo Nordisk Pharmaceuticals, UK. Diane Mellett, General Counsel at CAT and Company Secretary, will join the Board of Directors following the Company's AGM in February. Diane joined CAT in October 1997 as Vice President Legal Affairs and Company Secretary, having previously worked in private practice in the UK. Immediately prior to joining CAT, she worked for an American law firm in London and Chicago. In addition to being a solicitor, Diane is qualified as a US attorney admitted to the Illinois Bar.

https://www.bionity.com/en/news/42521/cambridge-antibody-technology-announces-changes-to-the-board-and-executive-group.html